Follow RSS for latest reports on this topicSAN-300 - Market Research and Reports
SAN-300, its novel antibody that inhibits very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule which plays a key role at sites of chronic inflammation. SAN-300 has potential application as a drug candidate in multiple inflammatory and autoimmune diseases, including Rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
SAN-300 was originally developed by Biogen Idec. In January 2009, Biogen licensed the antibody to Covella Pharmaceuticals and the deal was amended when Santarus acquired Covella in September 2010. In January 2014, Salix gained rights to the antibody, following its acquisition of Santarus.
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.